{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T03:40:14Z","timestamp":1686454814718},"reference-count":73,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.gastrohep.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T05:58:43Z","timestamp":1321250323000},"page":"635-640","source":"Crossref","is-referenced-by-count":1,"title":["Prevenci\u00f3n y tratamiento de la enfermedad venooclusiva hep\u00e1tica"],"prefix":"10.1016","volume":"34","author":[{"given":"Enric","family":"Carreras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2011.03.006_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1034\/j.1600-0609.2000.9r200.x","article-title":"Veno-occlusive disease of the liver after hemopoietic cell transplanttation","volume":"64","author":"Carreras","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-2008-1040578","article-title":"Liver disease after human marrow transplantation","volume":"7","author":"McDonald","year":"1987","journal-title":"Semin Liv Dis"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0015","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation:incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids:sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4065\/78.5.589","article-title":"Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0035","doi-asserted-by":"crossref","first-page":"G1187","DOI":"10.1152\/ajpgi.00229.2006","article-title":"Rat liver endothelial cells isolated by anti-CD31 immunomagnetic separation lack fenestrae and sieve plates","volume":"291","author":"DeLeve","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0040","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/hep.1840190515","article-title":"Venoocclusive disease of the liver after marrow transplantation:Histological correlates of clinical signs and symptoms","volume":"19","author":"Shulman","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","article-title":"Cellular target of cyclophosphamide toxicity in the murine liver-role of glutathione and site of metabolic activation","volume":"24","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I","article-title":"Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide","volume":"62","author":"Teicher","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0055","first-page":"873","article-title":"Drug-induced liver injury","volume":"2","author":"Pessayre","year":"1991"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0060","series-title":"Hemopoietic cell transplantation","first-page":"627","article-title":"Gastrointestinal and hepatic complications","author":"Strasser","year":"1999"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after Bone Marrow Transplantation:A cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0070","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0075","first-page":"3599","article-title":"Incidence and outcome of hepatic veno-occlusive disease (VOD) after blood and marrow transplantation (BMT):a prospective cohort study of the European group for Blood and Marrow Transplantation (EBMT)","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00007890-198506000-00005","article-title":"The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation","volume":"39","author":"McDonald","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0085","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver:development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0090","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure:response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0095","first-page":"75","article-title":"Risk factors for hepatic veno-occlusive disease following HLA-identical sibling marrow transplants for leukemia","volume":"17","author":"Rozman","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0100","first-page":"467","article-title":"Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide:incidence, risk factors, and clinical outcome","volume":"7","author":"Ozkaynak","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.1991.tb08621.x","article-title":"The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation","volume":"77","author":"Morgan","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan:correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0115","first-page":"759","article-title":"Busulfan pharmacokinetics in bone marrow transplant patients:is drug monitoring warranted?","volume":"14","author":"Schuler","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0120","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","article-title":"Optimization of busulfan dosage in children undergoing bone marrow transplantation:A pharmacokinetic study of dose escalation","volume":"80","author":"Yeager","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation","volume":"84","author":"Lee","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0130","first-page":"151","article-title":"Marrow transplantation for nonlymphophastic leukemia in first remission:toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation","volume":"1","author":"Deeg","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0135","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/1097-0142(19920601)69:11<2853::AID-CNCR2820691135>3.0.CO;2-2","article-title":"Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients","volume":"69","author":"Ozsahin","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0140","first-page":"797","article-title":"Total body irradiation in bone marrow transplantation:fractionated vs single dose. Acute toxicity and preliminary results","volume":"76","author":"Valls","year":"1989","journal-title":"Bull Cancer"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1705528","article-title":"Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT)","volume":"38","author":"Ramasamy","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0150","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","article-title":"Noethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation","volume":"92","author":"H\u00e4gglund","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2009.153","article-title":"Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation","volume":"45","author":"Chevallier","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0160","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","article-title":"Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation","volume":"47","author":"Marsa-Vila","year":"1991","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0165","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","article-title":"Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin:A prospective, randomized trial","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0170","first-page":"185","article-title":"Phase II trial of heparin prophylaxis for veno-occlusive of the liver in children undergoing bone marrow transplantation","volume":"18","author":"Rosenthal","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0175","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00007890-199604150-00014","article-title":"Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients","volume":"61","author":"Or","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0180","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/sj.bmt.1704087","article-title":"Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) alter hematopoietic stem cell transplantation:a prospective phase II study","volume":"31","author":"Forrest","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.1990.tb02583.x","article-title":"Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation","volume":"74","author":"Gluckman","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0190","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2141.1993.tb03152.x","article-title":"Prostaglandin E1 for prevention of hepatic veno-occlusive disease:results of a phase I study","volume":"84","author":"Bearman","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0195","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic stem cell transplantation. A randomized. double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation","volume":"64","author":"Ohashi","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0205","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","article-title":"Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation","volume":"100","author":"Ruutu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0210","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.V82.3.732.732","article-title":"Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial","volume":"82","author":"Attal","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0215","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V82.7.2025.2025","article-title":"A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation","volume":"82","author":"Clift","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0220","first-page":"795","article-title":"Hepatic veno-occlusive disease in pediatric stem cell transplantation:impact of pre-emptive antithrombin III replacement and combined antithrombin III\/defibrotide therapy","volume":"91","author":"Haussmann","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0225","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1399-3046.2009.01285.x","article-title":"Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution","volume":"14","author":"Lakshminarayanan","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0230","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1702387","article-title":"N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation","volume":"25","author":"Ringd\u00e9n","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0235","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.bmt.1705969","article-title":"A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Barkholt","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0240","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbmt.2004.01.002","article-title":"Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation","volume":"10","author":"Chalandon","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0245","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bmt.1705485","article-title":"Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide","volume":"38","author":"Corbacioglu","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1705696","article-title":"Prophylactic defibrotide in allogeneic stem cell transplantation:minimal morbidity and zero mortality from veno-occlusive disease","volume":"40","author":"Dignan","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0255","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","article-title":"Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure","volume":"103","author":"Versluys","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0260","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1705899","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation:update on defibrotide and other current investigational therapies","volume":"41","author":"Ho","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl2","key":"10.1016\/j.gastrohep.2011.03.006_bib0265","first-page":"S1","article-title":"Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complicatins in children at high risk:final results of a prospective phase II\/III muticentre study","volume":"45","author":"Corbacioglu","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0270","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","article-title":"Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation","volume":"17","author":"Palomo","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0275","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1704930","article-title":"Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity","volume":"35","author":"Eissner","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0280","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2008.03063.x","article-title":"Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis","volume":"6","author":"Hennan","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0285","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pupt.2010.09.003","article-title":"Peroxynitrite stimulates pulmonary artery endothelial and smooth muscle cell proliferation:Involvement of ERK and PKC","volume":"24","author":"Agbani","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0290","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.niox.2009.05.006","article-title":"Modulation of endothelial nitric oxide by plant-derived products","volume":"21","author":"Schmitt","year":"2009","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0295","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1703267","article-title":"Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation","volume":"28","author":"Tefferi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0300","first-page":"536","article-title":"Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS)","volume":"81","author":"de la Rubia","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0305","first-page":"643","article-title":"Transjugular intrahepatic portosystemic shunting for treatment of severe hepatic veno-occlusive disease","volume":"18","author":"Smith","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0310","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00007890-199004000-00035","article-title":"Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation","volume":"49","author":"Nimer","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0315","first-page":"421","article-title":"Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant","volume":"8","author":"Rappaport","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002770050358","article-title":"Hepatic veno-occlusive disease in pediatric stem cell recipients:successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin","volume":"76","author":"Schlegel","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0325","first-page":"567","article-title":"Prostaglandin E1 for prevention of hepatic veno-occlusive disease:results of a phase I study","volume":"19","author":"Bearman","year":"1991","journal-title":"Exp Hematol"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0330","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0335","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.bmt.1700985","article-title":"Antithombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation","volume":"20","author":"Morris","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0340","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1083-8791(98)50003-1","article-title":"A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfuntion syndrome during hematopoietic stem cell transplantation","volume":"4","author":"Haire","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0345","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1345\/aph.1D235","article-title":"Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity","volume":"38","author":"Ibrahim","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0350","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-3046.2006.00612.x","article-title":"Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease","volume":"11","author":"Eber","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0355","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1517\/14712598.8.8.1201","article-title":"Defibrotide: a review on clinical use and future development","volume":"8","author":"Larocca","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0360","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2010.02.009","article-title":"Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation:a multicenter, randomized, dose-finding trial","volume":"16","author":"Richardson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.gastrohep.2011.03.006_bib0365","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide:compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570511001397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570511001397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T03:14:55Z","timestamp":1686453295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570511001397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":73,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0210570511001397"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2011.03.006","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}